On December 5, 2017 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, reported that it will update data from its completed pilot study1 of NY‑ESO SPEAR T-cell therapy in multiple myeloma patients in the setting of autologous stem cell transplant (ASCT) presented at the annual ASH (Free ASH Whitepaper) meeting at the Georgia World Congress Center in Atlanta, Ga (Press release, Adaptimmune, DEC 5, 2017, View Source;p=RssLanding&cat=news&id=2321280 [SID1234522387]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During an oral presentation, Dr. Edward Stadtmauer, University of Pennsylvania Abramson Cancer Center, will present an update on all twenty-five multiple myeloma patients treated in Adaptimmune’s pilot study in the setting of ASCT. The data cut-off for the abstract was through July 2017, the data cut-off for the oral presentation was August 16, 2017.

Oral Presentation 845: Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02+ Patients with Advanced Multiple Myeloma: Long Term Follow‑up (NCT01352286)

Session: 703. Adoptive Immunotherapy: Gene Engineered T cells for Hematologic Malignancies

Time: Monday, December 11, 2017: 5:30 PM (EST)

Location: Bldg. B, Level 2, B206 (Georgia World Congress Center)

Result highlights from the abstract include:

Overall response rate (ORR) at day 100 was 76% (1 stringent complete response [sCR]; 12 very good partial response [VGPR]; 6 partial response [PR])
At year 1, 13 patients were progression free (52%) of which 11 were responders (1 sCR; 1 CR; 8 VGPR; 1 PR)
Three patients remain disease progression-free at 39, 56, and 61 months post T-cell infusion
Median progression free survival (PFS) was ~13 months (range 3-61 months)
Eleven of 25 patients (44%) are alive, and median survival was ~35 months (range 6-68 months)
Autologous GvHD (24%) was reported in 6 patients (3 G3, 3 ≤G2); all resolved with corticosteroids and supportive therapy
No fatal adverse events have been reported